Toggle navigation
Goals &
Objectives
Distinguished
Faculty
Education &
Resources
Contact
Us
Toggle navigation
Goals & Objectives
Distinguished Faculty
Education & Resources▼
CME Programs
Find a Clinician
SpeakerReady
Polling Questions
Conference Calendar
Refer a Colleague
Literature
Resources
Contact
Polling Questions
< All Questions
According to the webcast:
with James G. Pfaus, PhD, IF
The melanocortin agonist bremelanotide has shown to modulate dopamine release by which of the following mechanisms:
Activating dopamine release in the pre optic area (POA)
Activating dopamine release in the nucleus accumbens (NAc)
Activating dopamine release in the ventromedial nucleus (VMN)
All of the above
Your answers are confidential and will be used for educational purposes only.
Submit